DALLAS / Oct 17, 2024 / Business Wire / Enhabit, Inc. (NYSE: EHAB), a leading home health and hospice provider, today announced its recognition by the Institute for Healthcare Improvement (IHI) as an Age-Friendly Health Systems Participant.
Age-friendly Health Systems Participants are recognized for being on the journey to becoming an Age-Friendly Health System and have submitted a description of how they are putting four essential elements of care--the 4Ms--into practice with older patients.
"We're participating in this vital movement to share our practices and learn from others providing Age-Friendly Care," said Bud Langham, executive vice president of clinical excellence & strategy at Enhabit. "This initiative aligns with our vision to provide the best possible care for every older adult."
As part of the Age-Friendly Health Systems initiative, The John A. Hartford Foundation and the Institute for Healthcare Improvement, in partnership with the American Hospital Association and the Catholic Health Association of the United States, are helping hospitals and other care settings, such as home-based care, implement a set of evidence-based interventions specifically designed to improve care for older adults. These interventions focus on the 4Ms:
Enhabit joins a select number of health care systems worldwide, working to tailor care to patients' goals and preferences.
About Enhabit Home Health & Hospice
Enhabit Home Health & Hospice (Enhabit, Inc.) is a leading national home health and hospice provider working to expand what’s possible for patient care in the home. Enhabit's team of clinicians supports patients and their families where they are most comfortable, with a nationwide footprint spanning 256 home health locations and 112 hospice locations across 34 states. Enhabit leverages advanced technology and compassionate teams to deliver extraordinary patient care. For more information, visit ehab.com.
Last Trade: | US$8.11 |
Daily Change: | 0.05 0.62 |
Daily Volume: | 380,795 |
Market Cap: | US$411.100M |
August 06, 2025 May 07, 2025 November 06, 2024 August 06, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load